Gilberto de Castro Junior
@GilbertodeCas13
Followers
2K
Following
499
Media
19
Statuses
262
Médico Oncologista e Professor da Faculdade de Medicina da USP
Sao Paulo, Brazil
Joined February 2019
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated aNSCLC 📌The article persistently emphasizes the positive aspects of the 960 mg dosage. Defining a positive benefit-risk profile for a high dose, which has survival curves as below and
5
17
55
GFR Estimation Using β2-Microglobulin and β-Trace Protein in Adults With Solid Tumors: A Prospective Cross-Sectional Study https://t.co/wRbjni6EKy
@LAInker @CostalongaEC @GilbertodeCas13 @dr_luizgiljr @Htighiouart @ASLtufts @FMUSPoficial @TuftsMCKidney #VisualAbstract
1
5
6
Pls save the date for our @IASLC Latin America Conference in #lungcancer #LALCA24 with @AndresFCardonaZ @ogarrieta @LuciaViola9 @clarissamathias @LealTiciana @DrClaudiomartin @EdgardoSantosMD @ChristianRolfo @drgandara @fred_hirsch @cbaldotto @OLACANCER1 #LCSM #lungcancerawarness
3
18
53
@GilbertodeCas13 comenta o estudo ADAURA, apresentado em sessão plenária (LBA3) no #ASCO23 e publicado na NEJM, com resultados de osimertinibe adjuvante no CPCNP completamente ressecado, EGFRm e doença estágio IB, II ou IIIA - https://t.co/VKRkS9Qakn
@ASCO @Icesp_ #ONCONEWS
0
2
14
Important to stress: access to cancer medicines is a price problem and therefore needs drug price solutions, not only demanding increase access from governments. Work done with @MateusTrinconi, @marinazarzar and @GilbertodeCas13, all also from @Icesp_
1
2
15
Landmark paper by @CharlesSwanton group in @Nature: air pollution as a carcinogen in lung cancer.
Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵 https://t.co/q1ICykmVox
0
0
10
On #WorldHealthDay2023 , We reiterate the commitment with #UniversalHealthCoverage as a principle for equity, social justice, and the way to go! Protecting the vulnerable and promoting health for all is a human right !
0
5
12
A faringe é uma estrutura que conecta o nariz e a boca à laringe e ao esôfago. É o ponto de ligação entre o aparelho digestório e o respiratório. É formada por três regiões: nasofaringe, orofaringe e hipofaringe. O câncer pode se desenvolver em qualquer uma dessas regiões.
1
1
2
Summary🗓️:We will start 2023 with new strategies with immunotherapy or targeted therapies 👏🏻in advanced lung cancer. However, one size does not fit all 👕👗. 🔮Dynamic treatment approaches based on ctDNA and antibody drug conjugated will be relevant in 2023 @OncoAlert #lungcancer
1
67
197
Nivolumab produces ‘significant clinical activity’ in cutaneous squamous cell carcinoma https://t.co/cfnlZSCbzx
@GilbertodeCas13 @DrNabilSaba
healio.com
More than half of patients had an objective response to first-line nivolumab for locally advanced or metastatic cutaneous squamous cell carcinoma, phase 2 study results published in Cancer showed.I...
1
2
4
A SBOC lamenta o veto presidencial ao Projeto de Lei (PL) 5.307/2020, cujo objetivo é a manutenção do Programa Nacional de Apoio à Atenção Oncológica (Pronon) e do Programa Nacional de Apoio à Atenção da Saúde da Pessoa com Deficiência (Pronas/PCD). Veja https://t.co/vGFB0gIjSC
0
6
7
Em 2022 foram várias novidades e aprovações de medicamentos para o tratamento de neoplasias torácicas. Temos muitos motivos para comemorar! Boas Festas!
0
2
7
Fresh from the oven! Tumor glycolytic profiling (esp. PET-CT wTLG) can be a useful tool to increase granularity in PD-L1 profiles and help predict response of metastatic NSCLC to ICI. Thank you @GilbertodeCas13 and team! @SAGEJournals @GBOT_Alerta @IASLC
https://t.co/93mAaTyiV7
2
4
13
Conheça o movimento #pesquisasalvamvidas uma iniciativa do @projetocura_org para fomentar o financiamento, conscientização e regulação de pesquisas clínicas em oncologia. O LACOG é apoiador desse movimento! Para mais informações, acesse https://t.co/EN5bO2BegY
0
2
3
🔪🫁Na sala de cirurgia torácica, coordenada por drs. @DanielBonomi1 e @RicardoTerra12 foram discutidos a incorporação da tecnologia para tomada de decisão e melhoras dos resultados, Cirurgia minimamente invasiva, além de decisão compartilhada e multidisciplinar.
0
4
9
🔬🫁Na Sala de Patologia, coordenada pelos drs. @fabiotavora e @NGaglionone, foram abordadas a classificação histopatológica das neoplasias pulmonares, citopatologia, TNEs, patologia molecular. Sala cheia! Simpósio Nacional GBOT
0
5
9
🩺🫁Na sala de Pneumologia, coordenada pelos drs. @faibischew e Paula Werneck discutimos rastreamento, nódulos pulmonares, pré e pós operatório. Debates super atuais! Simpósio Nacional GBOT 2022
0
2
9
Here are this week's top stories with news from @US_FDA @MDAndersonNews @OncHahn @SeagenGlobal @COGorg @Icesp_ @EJonasch @GilbertodeCas13 & more! 1. https://t.co/RBqtLxdpE6 2. https://t.co/ZEXNkeDDhv 3. https://t.co/Z4ZVkz75h5 4. https://t.co/MIyxQHVIt3 5. https://t.co/Vdzs8E8eN2
0
3
6
#Pembrolizumab monotherapy given in the first-line setting continued to demonstrate durable clinical benefit vs chemotherapy in patients with PD-L1–positive, locally advanced/metastatic #NSCLC without EGFR/ALK alterations. #lcsm | @GilbertodeCas13 @Icesp_
https://t.co/lwMGiYujvo
0
1
3
Keynote 042 5-y f.u.: OS favored pembro vs. CT 1L. TPS ≥ 50%, HR 0.68 [0.57 to 0.81]; TPS ≥ 20%, HR 0.75 [0.64 to 0.87]; TPS ≥ 1%, HR 0.79 [0.70 to 0.89]); 5-year OS rates with pembro 21.9%, 19.4%, and 16.6%. No new tox. RR 15.2% 2nd course pembro.
ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or...
3
4
24